{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:34:29Z","timestamp":1787070869177,"version":"build-2736575974"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Rituximab is a chimeric monoclonal antibody against CD20. It is an established immunotherapeutic agent for non-Hodgkin's lymphoma. Even though rituximab has been used in clinics for decades, only 50% of the patients respond to rituximab therapy. To enhance the\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      effect of rituximab, it was labeled with Iodine-131 (\n                      <jats:sup>131<\/jats:sup>\n                      I) and combined effect of\n                      <jats:sup>131<\/jats:sup>\n                      I-rituximab and camptothecin (CPT) was studied on a tumor cell line expressing CD20.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>\n                      The aim is to study the magnitude of cell killing and the underlying mechanism responsible for enhancing\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      therapeutic efficacy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      Rituximab was labeled with\n                      <jats:sup>131<\/jats:sup>\n                      I by the iodogen method. Raji cells were pretreated with CPT (250 nM) for an hour followed by\n                      <jats:sup>131<\/jats:sup>\n                      I-rituximab (0.37 and 3.7 MBq) and incubated for 24 h in a humidified atmosphere of CO\n                      <jats:sub>2<\/jats:sub>\n                      incubator at 37\u00b0C. Subsequently, Raji cells were harvested and thoroughly washed to carry out studies of cellular toxicity, apoptosis, cell cycle, and mitogen-activated protein kinase (MAPK) pathways.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Maximal inhibition of cell proliferation and enhancement of apoptotic cell death was observed in the cells treated with the combination of CPT and\n                      <jats:sup>131<\/jats:sup>\n                      I-rituximab, compared to controls of CPT-treated and\n                      <jats:sup>131<\/jats:sup>\n                      I-rituximab-treated cells. Raji cells undergo G1 arrest after\n                      <jats:sup>131<\/jats:sup>\n                      I-rituximab treatment, which leads to apoptosis and was confirmed by the downregulation of bcl\n                      <jats:sub>xl<\/jats:sub>\n                      protein. Expression of p38 was decreased while an increase in phosphorylation of p38 was observed in the combination treatment of CPT and\n                      <jats:sup>131<\/jats:sup>\n                      I-rituximab.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      It was concluded from the findings that CPT enhanced\n                      <jats:sup>131<\/jats:sup>\n                      I-rituximab-induced apoptosis, G1 cell cycle arrest and p38 MAPK phosphorylation in Raji cells.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1012_19","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T04:26:59Z","timestamp":1627964819000},"page":"943-950","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Camptothecin enhances 131I-rituximab-induced G1-arrest and apoptosis in Burkitt lymphoma cells"],"prefix":"10.4103","volume":"17","author":[{"given":"Chandan","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna Mohan","family":"Repaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aanchal Udaynath","family":"Pareri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-19-20241021","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"R2-19-20241021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-62703-269-8_1","article-title":"Origin and pathogenesis of B cell lymphomas","volume":"971","author":"Seifert","year":"2013","journal-title":"Methods Mol Biol"},{"key":"R3-19-20241021","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.nucmedbio.2011.10.020","article-title":"Combined-modality radioimmunotherapy: Synergistic effect of paclitaxel and additive effect of bevacizumab","volume":"39","author":"Jang","year":"2012","journal-title":"Nucl Med Biol"},{"key":"R4-19-20241021","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.2174\/092986706777585004","article-title":"Review camptothecin: Current perspectives","volume":"13","author":"Li","year":"2006","journal-title":"Curr Med Chem"},{"key":"R5-19-20241021","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2174\/0929867311320120006","article-title":"Camptothecin resistance in cancer: Insights into the molecular mechanisms of a DNA-damaging drug","volume":"20","author":"Beretta","year":"2013","journal-title":"Curr Med Chem"},{"key":"R6-19-20241021","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.2008.001628","article-title":"Anti-CD20 monoclonal antibodies: Historical and future perspectives","volume":"95","author":"Lim","year":"2010","journal-title":"Haematologica"},{"key":"R7-19-20241021","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","article-title":"Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation","volume":"63","author":"Anderson","year":"1984","journal-title":"Blood"},{"key":"R8-19-20241021","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1038\/sj.onc.1210365","article-title":"Rituximab-induced inhibition of antiapoptotic cell survival pathways: Implications in chemo\/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions","volume":"26","author":"Bonavida","year":"2007","journal-title":"Oncogene"},{"key":"R9-19-20241021","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/sj.onc.1208349","article-title":"Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: Implications in chemosensitization and therapeutic intervention","volume":"24","author":"Jazirehi","year":"2005","journal-title":"Oncogene"},{"key":"R10-19-20241021","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00259-005-1770-7","article-title":"Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: Initial experience","volume":"32","author":"Bienert","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R11-19-20241021","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2010-02-269753","article-title":"Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients","volume":"117","author":"Leahy","year":"2011","journal-title":"Blood"},{"key":"R12-19-20241021","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1269\/jrr.47.183","article-title":"Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and-independent mechanisms","volume":"47","author":"Skvortsova","year":"2006","journal-title":"J Radiat Res"},{"key":"R13-19-20241021","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00411-009-0237-9","article-title":"Rituximab sensitizes a Burkitt lymphoma cell line to cell killing by X-irradiation","volume":"48","author":"Fengling","year":"2009","journal-title":"Radiat Environ Biophys"},{"key":"R14-19-20241021","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1615\/JEnvironPatholToxicolOncol.2013006843","article-title":"Cellular internalization and mechanism of cytotoxicity of 131I-rituximab in Raji cells","volume":"32","author":"Kumar","year":"2013","journal-title":"J Environ Pathol Toxicol Oncol"},{"key":"R15-19-20241021","doi-asserted-by":"crossref","first-page":"823","DOI":"10.4103\/0973-1482.140844","article-title":"Doxorubicin enhances (131)I-rituximab induced cell death in Raji cells","volume":"11","author":"Kumar","year":"2015","journal-title":"J Cancer Res Ther"},{"key":"R16-19-20241021","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2967\/jnumed.112.115170","article-title":"Radioimmunotherapy with 177Lu-DOTA-rituximab: Final results of a phase I\/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas","volume":"54","author":"Forrer","year":"2013","journal-title":"J Nucl Med"},{"key":"R17-19-20241021","first-page":"469","article-title":"Evaluation of the binding of radiolabeled rituximab to CD20-positive lymphoma cells: An in vitro feasibility study concerning low-dose-rate radioimmunotherapy with the alpha-emitter 227Th","volume":"22","author":"Melhus","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"key":"R18-19-20241021","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.nucmedbio.2010.05.010","article-title":"Radiolabeling of rituximab with (188)Re and (99m)Tc using the tricarbonyl technology","volume":"38","author":"Dias","year":"2011","journal-title":"Nucl Med Biol"},{"key":"R19-19-20241021","doi-asserted-by":"crossref","first-page":"ii","DOI":"10.3390\/ijms17050736","article-title":"Mechanisms of cell killing response from low linear energy transfer (LET) radiation originating from (177)Lu radioimmunotherapy targeting disseminated intraperitoneal tumor xenografts","volume":"17","author":"Yong","year":"2016","journal-title":"Int J Mol Sci"},{"key":"R20-19-20241021","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3724\/SP.J.1009.2013.00139","article-title":"Radioprotective effect of adenine on irradiation-induced apoptosis","volume":"11","author":"Wang","year":"2013","journal-title":"Chin J Nat Med"},{"key":"R21-19-20241021","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2174\/1874471007666140716115938","article-title":"Cellular and molecular effects of beta radiation from I-131 on human tumor cells: A comparison with gamma radiation","volume":"7","author":"Kumar","year":"2014","journal-title":"Curr Radiopharm"},{"key":"R22-19-20241021","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/09553002.2016.1144944","article-title":"Relevance of radiobiological concepts in radionuclide therapy of cancer","volume":"92","author":"Kumar","year":"2016","journal-title":"Int J Radiat Biol"},{"key":"R23-19-20241021","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1101\/gad.1199904","article-title":"Alkylating DNA damage stimulates a regulated form of necrotic cell death","volume":"18","author":"Zong","year":"2004","journal-title":"Genes Dev"},{"key":"R24-19-20241021","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/cdd.2013.111","article-title":"p53 talks to PARP: The increasing complexity of p53-induced cell death","volume":"20","author":"Wiman","year":"2013","journal-title":"Cell Death Differ"},{"key":"R25-19-20241021","doi-asserted-by":"crossref","first-page":"170325","DOI":"10.1155\/2012\/170325","article-title":"New insights into p53 signaling and cancer cell response to DNA damage: Implications for cancer therapy","volume":"2012","author":"Mirzayans","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"R26-19-20241021","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.12659\/MSM.899950","article-title":"Thioridazine sensitizes esophageal carcinoma cell lines to radiotherapy-induced apoptosis in vitro and in vivo","volume":"22","author":"Li","year":"2016","journal-title":"Med Sci Monit"},{"key":"R27-19-20241021","doi-asserted-by":"crossref","first-page":"e0151942","DOI":"10.1371\/journal.pone.0151942","article-title":"AZD2014 Radiosensitizes Oral Squamous Cell Carcinoma by Inhibiting AKT\/mTOR Axis and Inducing G1\/G2\/M Cell Cycle Arrest","volume":"11","author":"Yu","year":"2016","journal-title":"PLoS One"},{"key":"R28-19-20241021","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/0360-3016(90)90467-X","article-title":"Radiobiological aspects of low dose rates in radioimmunotherapy","volume":"18","author":"Fowler","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R29-19-20241021","doi-asserted-by":"crossref","first-page":"8590","DOI":"10.1038\/sj.onc.1207102","article-title":"The Bcl-2 family: Roles in cell survival and oncogenesis","volume":"22","author":"Cory","year":"2003","journal-title":"Oncogene"},{"key":"R30-19-20241021","first-page":"621","article-title":"Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine","volume":"17","author":"Emmanouilides","year":"2002","journal-title":"Cancer Biother Radiopharm"},{"key":"R31-19-20241021","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0360-3016(98)00325-3","article-title":"Ionizing radiation-induced MEK and Erk activation does not enhance survival of irradiated human squamous carcinoma cells","volume":"42","author":"Bonner","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R32-19-20241021","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/1947601913485414","article-title":"Mitogen-activated protein kinases and their role in radiation response","volume":"4","author":"Munshi","year":"2013","journal-title":"Genes Cancer"},{"key":"R33-19-20241021","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1126\/science.1072682","article-title":"Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases","volume":"298","author":"Johnson","year":"2002","journal-title":"Science"},{"key":"R34-19-20241021","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1182\/blood.V99.4.1314","article-title":"The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism","volume":"99","author":"Pedersen","year":"2002","journal-title":"Blood"},{"key":"R35-19-20241021","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1128\/MCB.20.13.4543-4552.2000","article-title":"Involvement of the MKK6-p38gamma cascade in gamma-radiation-induced cell cycle arrest","volume":"20","author":"Wang","year":"2000","journal-title":"Mol Cell Biol"},{"key":"R36-19-20241021","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3892\/ijo.2015.2814","article-title":"Combination treatment with triptolide and hydroxycamptothecin synergistically enhances apoptosis in A549 lung adenocarcinoma cells through PP2A-regulated ERK, p38 MAPKs and Akt signaling pathways","volume":"46","author":"Meng","year":"2015","journal-title":"Int J Oncol"},{"key":"R37-19-20241021","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1126\/science.270.5240.1326","article-title":"Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis","volume":"270","author":"Xia","year":"1995","journal-title":"Science"},{"key":"R38-19-20241021","first-page":"959","article-title":"Opposing role of JNK-p38 kinase and ERK1\/2 in hydrogen peroxide-induced oxidative damage of human trophoblast-like JEG-3 cells","volume":"7","author":"Tang","year":"2014","journal-title":"Int J Clin Exp Pathol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1012_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:55Z","timestamp":1787067475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1012_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1012_19","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}